PEGylated PLGA nanoparticles for the improved delivery of doxorubicin
Top Cited Papers
- 31 March 2009
- journal article
- Published by Elsevier BV in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 5 (4), 410-418
- https://doi.org/10.1016/j.nano.2009.02.002
Abstract
We hypothesize that the efficacy of doxorubicin (DOX) can be maximized and dose-limiting cardiotoxicity minimized by controlled release from PEGylated nanoparticles. To test this hypothesis, a unique surface modification technique was used to create PEGylated poly(lactic-co-glycolic acid) (PLGA) nanoparticles encapsulating DOX. An avidin-biotin coupling system was used to control poly(ethylene glycol) conjugation to the surface of PLGA nanoparticles, of diameter ~130 nm, loaded with DOX to 5% (wt/wt). Encapsulation in nanoparticles did not compromise the efficacy of DOX; drug-loaded nanoparticles were found to be at least as potent as free DOX against A20 murine B-cell lymphoma cells in culture and of comparable efficacy against subcutaneously implanted tumors. Cardiotoxicity in mice as measured by echocardiography, serum creatine phosphokinase (CPK), and histopathology was reduced for DOX-loaded nanoparticles as compared with free DOX. Administration of 18 mg/kg of free DOX induced a sevenfold increase in CPK levels and significant decreases in left ventricular fractional shortening over control animals, whereas nanoparticle-encapsulated DOX produced none of these pathological changes. From the Clinical Editor The efficacy of doxorubicin (DOX) may be maximized and dose-limiting cardiotoxicity minimized by controlled release from PEGylated nanoparticles. Administration of 18 mg/kg of free DOX induced a sevenfold increase in CPK levels and significant decreases in left ventricular fractional shortening in mice, whereas nanoparticle-encapsulated DOX produced none of these pathological changes.Keywords
This publication has 23 references indexed in Scilit:
- Nanoparticle therapeutics: an emerging treatment modality for cancerNature Reviews Drug Discovery, 2008
- Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibitionJournal of Controlled Release, 2006
- Enhanced and prolonged cross‐presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticlesImmunology, 2005
- Anti-CD19-Targeted Liposomal Doxorubicin Improves the Therapeutic Efficacy in Murine B-Cell Lymphoma and Ameliorates the Toxicity of Liposomes with Varying Drug Release RatesClinical Cancer Research, 2005
- Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targetingBiomaterials, 2005
- Cardiovascular Complications of Cancer TherapyCell Metabolism, 2004
- Suppression of Doxorubicin Cardiotoxicity by Overexpression of Catalase in the Heart of Transgenic MicePublished by Elsevier BV ,1996
- Biodegradable Microspheres in Drug DeliveryCritical Reviews in Therapeutic Drug Carrier Systems, 1995
- Anthracycline antitumour agentsInternational Journal of Clinical Pharmacy, 1986
- Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor ResponseScience, 1977